Andrea Nguyen, PA-C, MS, provides a detailed recap of her presentation on HS, which addressed the critical need for a multifactorial management approach, highlighting the severe psychosocial impacts, high DLQI scores, and permanent scarring that often stem from delayed or missed diagnoses. Clinicians reviewed the limitations of traditional Hurley staging alongside the implementation of newer clinical trial metrics like HiSCR scores, while emphasizing the crucial need to screen for and manage associated comorbidities. The presentation evaluated clinical data for established treatments, such as TNF inhibitors and IL-17 inhibitors, alongside promising future oral JAK inhibitors.
